Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

nork Petersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., Scaroni, C., Ravichandran, S., Kandra, A., Biller, B. M. K.
Argitaratua izan da Endocrine (2017)